OCGN Ocugen
- 1.9100
- -0.0700-3.54%
- 1.9295
- +0.0195+1.02%
Ocugen News
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday.Shares of DXC Technology Company (NYSE:DXC) fell sharply in today's pre-market trading afte
Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Nayax Ltd. (NASDAQ:NYAX) fell sharply in today's pre-market trading following weak
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Price Target Maintained With a $5.00/Share by Chardan Capital
Ocugen Price Target Maintained With a $5.00/Share by Chardan Capital
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
Ocugen (OCGN) said Wednesday it has completed dosing of the second group of its phase 1/2 clinical study of its experimental gene modifier therapy candidate OCU41OST, being developed as a one-time tre
HC Wainwright & Co. : The Ocugen (OCGN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $7.00.
HC Wainwright & Co. : The Ocugen (OCGN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $7.00.
HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen with a Buy and maintains $7 price target.
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/22/2024 197.62% Chardan Capital $4 → $
Buy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical Pipeline
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Q1 2024 Ocugen Inc Earnings Call
Ocugen Announces Dosing Completion of Subjects With Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and
Earnings Call Summary | Ocugen(OCGN.US) Q1 2024 Earnings Conference
The following is a summary of the Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript:Financial Performance:Ocugen's R&D expenses for Q1 2024 were $6.8 million, a decrease compared to $10.2 million i
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Ocugen 1Q Loss/Shr 5c >OCGN
Ocugen 1Q Loss/Shr 5c >OCGN
Press Release: Ocugen Provides Business Update With First Quarter 2024 Financial Results
Ocugen Provides Business Update with First Quarter 2024 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET -- All three first-in-class modifier gene therapy product candidates
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0.06) Estimate, Sales $1.014M Up From $443.000K YoY
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0.06) Estimate, Sales $1.014M Up From $443.000K YoY
Ocugen | 10-Q: Quarterly report
Ocugen Provides Business Update With First Quarter 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ETAll three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 B
Ocugen Q1 2024 Earnings Preview
Analysis
Price Target
No Data
